# Vlado Perkovic

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/vlado-perkovic-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,466 |
| Field | Diabetes Treatment and Management |
| h-index | 11 |
| i10-index | 12 |
| Last Known Institution | UNSW Sydney |
| OpenAlex ID | https://openalex.org/A5108135795 |
| Works | 58 |

## Researcher papers

- [Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes](https://scholariq.org/papers/effects-of-semaglutide-on-chronic-kidney-disease-in-patients-with-type-2/)
- [Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials](https://scholariq.org/papers/effects-of-glp-1-receptor-agonists-on-kidney-and-cardiovascular-disease-outcomes/)
- [Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials](https://scholariq.org/papers/efficacy-and-safety-of-sglt2-inhibitors-with-and-without-glucagon-like-peptide-1/)
- [Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial](https://scholariq.org/papers/effects-of-semaglutide-on-heart-failure-outcomes-in-diabetes-and-chronic-kidney/)
- [SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria](https://scholariq.org/papers/sglt2-inhibitors-and-kidney-outcomes-by-glomerular-filtration-rate-and/)
- [Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial](https://scholariq.org/papers/cardiovascular-outcomes-with-semaglutide-by-severity-of-chronic-kidney-disease/)
- [Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial](https://scholariq.org/papers/sibeprenlimab-in-iga-nephropathy-interim-analysis-of-a-phase-3-trial/)
- [From progression to remission: a new paradigm for success in chronic kidney disease](https://scholariq.org/papers/from-progression-to-remission-a-new-paradigm-for-success-in-chronic-kidney/)
- [Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis](https://scholariq.org/papers/effects-of-semaglutide-with-or-without-concomitant-mineralocorticoid-receptor/)
- [Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria](https://scholariq.org/papers/effects-of-sodium-glucose-cotransporter-2-inhibitors-by-diabetes-status-and/)
- [Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial](https://scholariq.org/papers/kidney-and-survival-outcomes-with-semaglutide-by-ckd-severity-in-the-flow-trial/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)

## Researcher university

- [UNSW Sydney](https://scholariq.org/institutions/unsw-sydney/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.